619 related articles for article (PubMed ID: 17709460)
41. Comparative Effectiveness of First-Line and Alternative Antibiotic Regimens in Hospitalized Patients With Nonsevere Community-Acquired Pneumonia: A Multicenter Retrospective Cohort Study.
Bai AD; Srivastava S; Wong BKC; Digby GC; Razak F; Verma AA
Chest; 2024 Jan; 165(1):68-78. PubMed ID: 37574164
[TBL] [Abstract][Full Text] [Related]
42. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
43. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
[TBL] [Abstract][Full Text] [Related]
44. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
Murcia JM; González-Comeche J; Marín A; Barberán J; Granizo JJ; Aguilar L; González-Moreno J; González-Pina B; López-Dupla M; Irurzun J;
Clin Microbiol Infect; 2009 Nov; 15(11):1046-50. PubMed ID: 19548926
[TBL] [Abstract][Full Text] [Related]
45. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
[TBL] [Abstract][Full Text] [Related]
46. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
[TBL] [Abstract][Full Text] [Related]
47. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
[TBL] [Abstract][Full Text] [Related]
48. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
[TBL] [Abstract][Full Text] [Related]
49. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Wenisch C; Krause R; Széll M; Laferl H
Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
[TBL] [Abstract][Full Text] [Related]
50. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
[TBL] [Abstract][Full Text] [Related]
51. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia.
Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
Respir Med; 2012 Mar; 106(3):451-8. PubMed ID: 22182341
[TBL] [Abstract][Full Text] [Related]
52. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
[TBL] [Abstract][Full Text] [Related]
53. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
[TBL] [Abstract][Full Text] [Related]
54. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Ewig S; Hecker H; Suttorp N; Marre R; Welte T;
J Infect; 2011 Mar; 62(3):218-25. PubMed ID: 21276814
[TBL] [Abstract][Full Text] [Related]
55. Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients.
Simonetti AF; van Werkhoven CH; Schweitzer VA; Viasus D; Carratalà J; Postma DF; Oosterheert JJ; Bonten MJM
Clin Microbiol Infect; 2017 Oct; 23(10):774.e1-774.e7. PubMed ID: 28336384
[TBL] [Abstract][Full Text] [Related]
56. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
[TBL] [Abstract][Full Text] [Related]
57. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.
Nie W; Li B; Xiu Q
J Antimicrob Chemother; 2014 Jun; 69(6):1441-6. PubMed ID: 24535276
[TBL] [Abstract][Full Text] [Related]
58. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
59. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
60. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
